Abstract
To compare the survival rates and toxicities of prophylactic extended-field radiation therapy (EFRT) and pelvic radiation therapy (PRT) among cervical cancer patients with 2018 FIGO stage IIIC1 disease. We retrospectively analyzed patients with 2018 FIGO stage IIIC1 disease who were treated with definitive concurrent chemoradiotherapy at our institute between 2011 and 2015. A dose of 50.4 Gy in 28 fractions was delivered to the pelvic region (by PRT) or the pelvic plus para-aortic lymph node region (by EFRT) with intensity-modulated radiation therapy. The first-line regimen of concurrent chemotherapy was weekly cisplatin. A total of 280 patients were included, with 161 patients treated with PRT and 119 patients treated with EFRT. After propensity score matching (1:1), 71 pairs of patients were selected. The respective 5-year rates of the patients treated with PRT and EFRT were 61.9% and 85.0% for overall survival (p=0.025), 53.0% and 77.9% for disease-free survival (DFS, p=0.004) after matching. In the subgroup analysis, patients were grouped into a high-risk group (122 patients) and a low-risk group (158 patients) based on three factors: positive common iliac lymph nodes, ≥ 3 pelvic lymph nodes and 2014 FIGO stage IIIB disease. In both the high-risk and low-risk groups, EFRT significantly improved DFS compared with PRT. The rates of ≥ grade 3 chronic toxicities were 1.2% and 5.9% in the PRT and EFRT groups, respectively (p=0.067). In comparison to PRT, prophylactic EFRT was associated with improved OS, DFS, and PALN control in cervical cancer patients with FIGO stage IIIC1 disease. The incidence of grade 3 or higher toxicities was higher in the EFRT group than in the PRT group, although the difference was not significant.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
